Report on the Clinicopathological Characteristics of 548 Romanian Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs

#1774

Introduction: In Romania, treatment with somatostatin analogs (SSA) for neuroendocrine tumors (NETs) is based on the National Clinical Practice Guideline for the Diagnostic and Treatment of NETs and is reimbursed by the National Health Insurance Company since 2008.

Aim(s): We reviewed the database of Romanian patients with NETs that received reimbursed SSA between 2008 and 2015 in order to describe their characteristics.

Materials and methods: The National Health Insurance Company approved access to the database.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Fica S, Ghemigian A, Ghervan C, Croitoru A, Pirvulescu I,

Keywords: neuroendocrine tumors, somatostatin analogs,